Q-omics provides the consensus-scored SUPT7L profile across patient tissues and cancer cell-line models. SUPT7L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SUPT7L is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SUPT7L RNA expression shows 20,410 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where SUPT7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUPT7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUPT7L survival associations across molecular data types. SUPT7L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUPT7L RNA expression–survival associations across cancer types. High SUPT7L expression shows unfavorable associations in LIHC, ACC, BLCA, MESO, UVM and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SUPT7L RNA expression.
This table summarizes SUPT7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SUPT7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUPT7L shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LIHC, BLCA and KIRC. The HNSC box plot shows higher SUPT7L RNA expression in tumor versus normal tissue (log2 FC = +1.024, t-test p < 0.001).
This table shows molecular features associated with SUPT7L in patient tissues and cancer cell lines. In patient samples, SUPT7L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUPT7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
